Gadavist

Renal artery occlusion, Coronary Artery Disease (CAD), MRI + 1 more
Treatment
20 Active Studies for Gadavist

What is Gadavist

GadobutrolThe Generic name of this drug
Treatment SummaryGadobutrol is an intravenous medication used to help diagnose and detect problems with the blood brain barrier and central nervous system through magnetic resonance imaging (MRI). It is approved for use in adults and children over 2 years old. Patients with kidney problems may be at risk of developing nephrogenic systemic fibrosis (NSF). Symptoms of NSF include skin discoloration, joint stiffness, trouble moving, burning, itching, swelling, scaling, hardening, and tightening of skin, pain in hip bones or ribs, or muscle weakness. Common side effects include headache, nausea, feeling hot, abnormal taste, warmth, burning,
Gadavistis the brand name
image of different drug pills on a surface
Gadavist Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Gadavist
Gadobutrol
2011
2

Effectiveness

How Gadavist Affects PatientsGadobutrol shortens the time it takes for protons in plasma to relax. At an average temperature and pH, and a magnetic field strength of 1.5T, it has a relaxivity of 5.2L/(mmol·sec). Higher concentrations of Gadobutrol lead to a shorter time for protons to relax, and this can improve tissue visualization. The magnetic field strength does not have a strong effect on the relaxivity of Gadobutrol.
How Gadavist works in the bodyGadolinium is a dye used in Magnetic Resonance Imaging (MRI) to create clearer images. It does this by altering the intensity of radiofrequency signals in the tissue, which can be seen as differences in brightness. The dye works by shortening the time it takes for these signals to relax, which makes them appear brighter on an MRI. The amount of signal enhancement achieved depends on the concentration of Gadolinium in the tissue, the MRI field strength, and the ratio of transverse and longitudinal signals. The recommended dose produces the most noticeable effects in T1-weighted sequences, while high concentrations used during bolus injections can lead

When to interrupt dosage

The proposed dosage of Gadavist is contingent upon the determined condition, for example Renal Artery Stenosis, Supravalvular Aortic Stenosis and Central Nervous System. The amount of dosage is contingent upon the method of administration (e.g. Solution - Intravenous or Solution) as outlined in the table below.
Condition
Dosage
Administration
MRI
, 604.72 mg/mL
, Intravenous, Solution, Solution - Intravenous, Injection, Injection - Intravenous
Renal artery occlusion
, 604.72 mg/mL
, Intravenous, Solution, Solution - Intravenous, Injection, Injection - Intravenous
Breast
, 604.72 mg/mL
, Intravenous, Solution, Solution - Intravenous, Injection, Injection - Intravenous
Coronary Artery Disease (CAD)
, 604.72 mg/mL
, Intravenous, Solution, Solution - Intravenous, Injection, Injection - Intravenous

Warnings

Gadavist has one contraindication, and so it should not be employed while having any of the conditions in the table below.Gadavist Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Gadobutrol may interact with Pulse Frequency
Common Gadavist Drug Interactions
Drug Name
Risk Level
Description
Gadavist Toxicity & Overdose RiskIn animal studies, a single high dose of the drug was found to be lethal in rodents, which is hundreds of times higher than the standard single dose used in humans. No tests have been done for carcinogenicity or mutagenesis, but tests have not shown any signs of fertility or reproductive impairment in animals given doses much higher than humans would receive. Local irritation and inflammation may occur if the drug leaks around veins during administration.
image of a doctor in a lab doing drug, clinical research

Gadavist Novel Uses: Which Conditions Have a Clinical Trial Featuring Gadavist?

11 active trials are presently assessing the potential of Gadavist for use in Renal Artery Stenosis, Central Nervous System Imaging and Magnetic Resonance (MR) Scans.
Condition
Clinical Trials
Trial Phases
MRI
14 Actively Recruiting
Phase 2, Not Applicable, Phase 3
Renal artery occlusion
0 Actively Recruiting
Coronary Artery Disease (CAD)
1 Actively Recruiting
Not Applicable
Breast
5 Actively Recruiting
Not Applicable, Phase 1, Phase 2

Gadavist Reviews: What are patients saying about Gadavist?

1Patient Review
6/4/2017
Gadavist for MRI Scan
This treatment is incredibly dangerous and can cause irreversible damage to the central nervous system and all organs. It is a toxic metal, and I would avoid it at all cost.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about gadavist

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is gadolinium the same as gadavist?

"Gadavist is used with magnetic resonance imaging (MRI) to help your radiologist better see and evaluate the blood vessels in and around your brain.

Gadavist is a prescription medicine that is a gadolinium-based contrast agent (GBCA). Gadavist is used with magnetic resonance imaging (MRI) in order to help the radiologist get a better image of the blood vessels in and around the brain."

Answered by AI

How long does it take for gadavist stay in your system?

"This text is discussing how much of a given dose is eliminated via urine after administration, and states that more than 50% is eliminated within two hours, and more than 90% is eliminated within 12 hours. It also mentions that extra-renal elimination is negligible, meaning that very little of the drug is eliminated through means other than urine."

Answered by AI

What are the side effects of gadavist?

"I'm experiencing a headache, nausea, vomiting, malaise, dizziness, an abnormal or unpleasant taste in my mouth, feeling hot, and/or a numb or tingly feeling."

Answered by AI

What is gadavist used for?

"Gadavist is approved for use with MRI to detect and visualize areas of the central nervous system with a disrupted blood-brain barrier or abnormal vascularity in pediatric patients less than 2 years old, including term neonates."

Answered by AI

Clinical Trials for Gadavist

Have you considered Gadavist clinical trials? We made a collection of clinical trials featuring Gadavist, we think they might fit your search criteria.
Have you considered Gadavist clinical trials? We made a collection of clinical trials featuring Gadavist, we think they might fit your search criteria.
Have you considered Gadavist clinical trials? We made a collection of clinical trials featuring Gadavist, we think they might fit your search criteria.